Miguel Bronchud: Parallel thinking in developmental therapeutics

Miguel Bronchud, Co-Founder of Regenerative Medicine Solutions, shared on LinkedIn:

”What we learned in the oncology setting-trying to better understand cancers – can also be useful to treat other diseases? And viceversa? Parallel thinking in developmental therapeutics?

Hidradenitis suppurativa – an unpleasant skin disease that causes repeated pus infection and depression can now be treated with monoclonal antibodies.

It is a chronic, recurrent, inflammatory skin disorder with a debilitating course and a profoundly negative effect on quality of life. Hidradenitis suppurativa usually develops in puberty or in the young adulthood and is clinically defined by inflammatory nodules, abscess, tunnels, and scars predominantly distributed in flexural areas accompanied with pain, unpleasant odour, and unaesthetic appearance. Patients are often young and have difficulty in socializing because of their skin condition (axillary, groin abscess or skin scars and pus); often requiring antibiotics but also antidepressants…

Management of this chronic disease is challenging, and it can take some months to diagnose correctly but the introduction of biologic therapies and monoclonal antibodies has led to a therapeutic revolution in a cutaneous disorder historically considered a surgical disease. The biological agents currently used in the treatment of adult moderate-to-severe hidradenitis suppurativa are the anti-tumour necrosis factor (TNF)-α adalimumab and the IL-17A inhibitor secukinumab. Bimekizumab is a humanised, full-length IgG1 monoclonal antibody that inhibits simultaneously IL-17A and IL-17F and in April, 2024, it received marketing authorisation in the EU in the treatment of hidradenitis suppurativa. Thus, the therapeutic indications for bimekizumab in the EU include plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa.

1. European Medicines Agency
Bimzelx: EPAR product information.
Read further.

2. Read further.”

Source: Miguel Bronchud/LinkedIn